Abstract
Histologic variants of prostate acinar adenocarcinoma, ductal adenocarcinoma, neuroendocrine tumors, and other carcinomas account for 5–10% of prostate carcinomas and frequently are associated with ordinary acinar prostate adenocarcinoma. The morphologic spectrum of histologic variants of acinar adenocarcinoma ranges from tumors often resembling benign conditions, such as foamy and pseudohyperplastic carcinoma, to highly aggressive forms, such as sarcomatoid carcinoma. These histologic variants of acinar adenocarcinoma, ductal adenocarcinoma, neuroendocrine tumors, and other carcinomas often differ from acinar carcinoma in clinical, immunophenotypic, ultrastructural, or genetic features. Some of this histologic spectrum also differ in prognosis and may necessitate a different therapeutic approach. This chapter outlines important clinical and pathologic characteristics of histologic variants of acinar adenocarcinoma, ductal adenocarcinoma, neuroendocrine tumors, and other carcinomas.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Humphrey PA. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. Mod Pathol. 2018;31:S64–70.
Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer; 2016.
Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol. 2012;43:313–24.
Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010;34:35–43.
Yaskiv O, Cao D, Humphrey PA. Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol. 2010;34:556–61.
Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;68:825–30.
Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009;22:1176–85.
Parwani AV, Herawi M, Epstein JI. Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol. 2006;30:1254–9.
Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol. 2006;30:1316–21.
Hameed O, Humphrey PA. Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2006;19:899–906.
Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol. 2008;32:1060–7.
Zhou M. High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol. 2018;31:S71–9.
Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol. 1999;23:1471–9.
Dube VE, Farrow GM, Greene LF. Prostatic adenocarcinoma of ductal origin. Cancer. 1973;32:402–9.
Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Cancer Netw. 2014;12:719–26.
Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756–67.
Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011;24:820–8.
Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37:726–34.
Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol. 2006;125:675–81.
McKenney JK, Amin MB, Srigley JR, Jimenez RE, Ro JY, Grignon DJ, et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Pathol. 2004;28:1289–98.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shah, R.B., Zhou, M. (2019). Histologic Variants of Acinar Adenocarcinoma, Ductal Adenocarcinoma, Neuroendocrine Tumors, and Other Carcinomas. In: Prostate Biopsy Interpretation. Springer, Cham. https://doi.org/10.1007/978-3-030-13601-7_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-13601-7_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13600-0
Online ISBN: 978-3-030-13601-7
eBook Packages: MedicineMedicine (R0)